Zahi Touma

Zahi Touma

Auto-generated profile, based on publicly available information

Zahi Touma

University of Toronto Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2019 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
MAMartin Aringer
Martin Aringer
KCKaren Costenbader
Karen Costenbader
DDDavid Daikh
David Daikh
RBRalph Brinks
Ralph Brinks
MMMarta Mosca
Marta Mosca
SJSindhu Johnson
Sindhu Johnson
Objective: To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).Methods: This international initiative had four phases. 1) Evaluation of antinuclear antibody (ANA) as an entry criterion through systematic review and meta‐regression of the literature and criteria generation through an international Delphi exercise, an early patient cohort, and a patient survey. 2) Criteria reduction by Delphi and nominal group technique exercises. 3) Criteria definition and weighting based on criterion performance and on results of a multi‐criteria decision analysis. 4) Refinement of weights and threshold scores in a new derivation cohort of 1,001 subjects and validation compared with previous criteria in a new validation cohort of 1,270 subjects.Results: The 2019 EULAR/ACR classification criteria for SLE include positive ANA at least once as obligatory entry criterion; followed by additive weighted criteria grouped in 7 clinical (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and 3 immunologic (antiphospholipid antibodies, complement proteins, SLE‐specific antibodies) domains, and weighted from 2 to 10. Patients accumulating ≥10 points are classified. In the validation cohort, the new criteria had a sensitivity of 96.1% and specificity of 93.4%, compared with 82.8% sensitivity and 93.4% specificity of the ACR 1997 and 96.7% sensitivity and 83.7% specificity of the Systemic Lupus International Collaborating Clinics 2012 criteria.Conclusion: These new classification criteria were developed using rigorous methodology with multidisciplinary and international input, and have excellent sensitivity and specificity. Use of ANA entry criterion, hierarchically clustered, and weighted criteria reflects current thinking about SLE and provides an improved foundation for SLE research.

16 June 2016 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
AKArvind Kaul
Arvind Kaul
CGCaroline Gordon
Caroline Gordon
MCMary K. Crow
Mary K. Crow
ZTZahi Touma
Zahi Touma
MUMurray Urowitz
Murray Urowitz
GHGraham Hughes
Graham Hughes

1 October 2018 in The Lancet
Verified
Journal Article
Closed access
RVRonald F van Vollenhoven
Ronald F van Vollenhoven
BHBevra H Hahn
Bevra H Hahn
GTGeorge C Tsokos
George C Tsokos
CWCarrie L Wagner
Carrie L Wagner
PLPeter Lipsky
Peter Lipsky
SRShawn Rose
Shawn Rose

27 December 2016 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
APAri Polachek
Ari Polachek
ZTZahi Touma
Zahi Touma
MAMelanie Anderson
Melanie Anderson
LELihi Eder
Lihi Eder

14 May 2018 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
RSRahul Shinde
Rahul Shinde
KHKebria Hezaveh
Kebria Hezaveh
MHMarie Jo Halaby
Marie Jo Halaby
AKAndreas Kloetgen
Andreas Kloetgen
ACAnkur Chakravarthy
Ankur Chakravarthy
TMTracy L. McGaha
Tracy L. McGaha

9 July 2024 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
EEEllen B.M. Elsman
Ellen B.M. Elsman
LMLidwine Mokkink
Lidwine Mokkink
CTCaroline B. Terwee
Caroline B. Terwee
DBDorcas Beaton
Dorcas Beaton
JGJoel Gagnier
Joel Gagnier
MOMartin Offringa
Martin Offringa
Although comprehensive and widespread guidelines on how to conduct systematic reviews of outcome measurement instruments (OMIs) exist, for example from the COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) initiative, key information is often missing in published reports. This article describes the development of an extension of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guideline: PRISMA-COSMIN for OMIs 2024. The development process followed the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) guidelines and included a literature search, expert consultations, a Delphi study, a hybrid workgroup meeting, pilot testing, and an end-of-project meeting, with integrated patient/public involvement. From the literature and expert consultation, 49 potentially relevant reporting items were identified. Round 1 of the Delphi study was completed by 103 panelists, whereas round 2 and 3 were completed by 78 panelists. After 3 rounds, agreement (≥67%) on inclusion and wording was reached for 44 items. Eleven items without consensus for inclusion and/or wording were discussed at a workgroup meeting attended by 24 participants. Agreement was reached for the inclusion and wording of 10 items, and the deletion of 1 item. Pilot testing with 65 authors of OMI systematic reviews further improved the guideline through minor changes in wording and structure, finalized during the end-of-project meeting. The final checklist to facilitate the reporting of full systematic review reports contains 54 (sub)items addressing the review's title, abstract, plain language summary, open science, introduction, methods, results, and discussion. Thirteen items pertaining to the title and abstract are also included in a separate abstract checklist, guiding authors in reporting for example conference abstracts. PRISMA-COSMIN for OMIs 2024 consists of two checklists (full reports; abstracts), their corresponding explanation and elaboration documents detailing the rationale and examples for each item, and a data flow diagram. PRISMA-COSMIN for OMIs 2024 can improve the reporting of systematic reviews of OMIs, fostering their reproducibility and allowing end-users to appraise the quality of OMIs and select the most appropriate OMI for a specific application. NOTE: This paper was jointly developed by Journal of Clinical Epidemiology, Quality of Life Research, Journal of Patient Reported Outcomes, Health and Quality of Life Outcomes and jointly published by Elsevier Inc, Springer Nature Switzerland AG, and BioMed Central Ltd., part of Springer Nature. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.